IA
BCTX

Insight Advisors’s Briacell Therapeutics BCTX Stock Holding History

Insight Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-113
Closed -$140K – 318
2021
Q4 		$140K Buy
+113
New +$148K 0.04% 304

Other funds holding BCTX

KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Insight Advisors's BCTX Position: Q1 2022 in Review

Insight Advisors sold out of Briacell Therapeutics (BCTX) in Q1 2022, closing a stake of 113 shares — an estimated $140K sold.

Insight Advisors first reported a position in BCTX in Q4 2021 and held it in 1 quarter. The position peaked at $140K in Q4 2021. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2022.

  • Insight Advisors reported no remaining Briacell Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Insight Advisors sold 113 Briacell Therapeutics shares in Q1 2022, an estimated $140K.
  • Insight Advisors first reported a position in Briacell Therapeutics in Q4 2021 and held it in 1 quarter.
  • Insight Advisors's Briacell Therapeutics position peaked at $140K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2022.

Based on Insight Advisors's 13F filing for Q1 2022, filed 13 May 2022.